(3aS,4S,6R,6aR)-2,2-dimethyl-6-prop-1-en-2-yl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol | 915214-87-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (3aS,4S,6R,6aR)-2,2-dimethyl-6-prop-1-en-2-yl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol
• CAS: 915214-87-8
• 化学式: C₁₁H₁₈O₃
• 分子量: 198.262
• InChiKey: XJSWGMMOHYNRFN-RGOKHQFPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3aS,4S,6R,6aR)-2,2-dimethyl-6-prop-1-en-2-yl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 在 吡啶 、 2,6-二甲基吡啶 、 4-二甲氨基吡啶 、 sodium periodate 、 四氧化锇 、 N,N-diethylaniline borane 、 (S)-perhydropyrrolo[1,2-c][1,3,2]oxazaborole-based compound 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 17.5h， 生成 Acetic acid (R)-1-((3aR,4R,6S,6aS)-6-hydroxy-2,2-dimethyl-tetrahydro-cyclopenta[1,3]dioxol-4-yl)-ethyl ester
  参考文献：
  名称：

  5‘-Methylaristeromycin and Related Derivatives

  摘要：

  The biological versatility of aristeromycin (carbocyclic adenosine) is limited by accompanying cytotoxicity caused ostensibly by the intracellular formation of its 5'-nucleotide derivatives. Aristeromycin derivatives that offered steric interference to this transformation at the C-5' center were sought. This paper describes the facile stereospecific synthesis, where necessary, of such C-5'-methylated aristeromycin derivatives.

  DOI：

  10.1021/jo0612170
• 作为产物：
  描述：

  (3aR,6R,6aR)-6-Isopropenyl-2,2-dimethyl-tetrahydro-cyclopenta[1,3]dioxol-4-one 在 二异丁基氢化铝 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 反应 2.5h， 以89%的产率得到(3aS,4S,6R,6aR)-2,2-dimethyl-6-prop-1-en-2-yl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol
  参考文献：
  名称：

  5‘-Methylaristeromycin and Related Derivatives

  摘要：

  The biological versatility of aristeromycin (carbocyclic adenosine) is limited by accompanying cytotoxicity caused ostensibly by the intracellular formation of its 5'-nucleotide derivatives. Aristeromycin derivatives that offered steric interference to this transformation at the C-5' center were sought. This paper describes the facile stereospecific synthesis, where necessary, of such C-5'-methylated aristeromycin derivatives.

  DOI：

  10.1021/jo0612170

文献信息

• Spirobicyclic analogues
  申请人：Janssen Pharmaceutica NV

  公开号：US11059850B2

  公开（公告）日：2021-07-13

  The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式（I）的新型螺环类似物，其中各变量具有权利要求中定义的含义。根据本发明的化合物可用作 PRMT5 抑制剂。本发明进一步涉及包含所述化合物作为活性成分的药物组合物以及所述化合物作为药物的用途。
• NOVEL SPIROBICYCLIC ANALOGUES
  申请人：Janssen Pharmaceutica NV

  公开号：US20200369707A1

  公开（公告）日：2020-11-26

  The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
• Novel Spirobicyclic Analogues
  申请人：Janssen Pharmaceutica NV

  公开号：US20210380627A1

  公开（公告）日：2021-12-09

  The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.